Ethical aspects of soft tissue engineering for congenital birth defects in children - what do experts in the field say? by Oerlemans, A.J.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/88695
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Ethical Aspects of Soft Tissue Engineering
for Congenital Birth Defects in Children—
What Do Experts in the Field Say?
Anke J.M. Oerlemans, M.A., M.Sc.,1 Catarina H.C.M.L. Rodrigues, M.A.,2
Marian A. Verkerk, Ph.D.,2 Paul P. van den Berg, M.D., Ph.D.,3 and Wim J.M. Dekkers, M.D., Ph.D.1
This article is part of the EuroSTEC project, which aims at developing tissue engineering-based treatments for
structural disorders present at birth. EuroSTEC is positioned at the intersection of three areas with their own
ethical issues: (1) regenerative medicine, (2) research with pregnant women and fetuses, and (3) research with
neonates. Because of the overlap of these three areas in this project, we can expect to be confronted with new
ethical challenges. To be able to respond adequately and timely to current and possible future ethical issues, a
prospective and anticipatory ethical analysis is essential. To obtain a first survey of ethical issues that might arise
during the different phases of the project, the Delphi method was used. The professionals directly involved in the
EuroSTEC project were questioned about their views on possible ethical issues. The first round yielded 27 ethical
issues, which the respondents were asked to prioritize in the second round. For the fundamental research phase,
issues deemed most important were privacy and informed consent of the tissue donor. For the animal experi-
mentation phase, three issues were mentioned (in order of decreasing priority): the suffering of animals, the use
of animals as means to an end, and the limited adequacy of the animal models. Issues that were deemed most
important during the clinical (trial) phase pertained to the problem of weighing risks and benefits for the fetus/
child and the pregnant woman.
Introduction
EuroSTEC is an Integrated Project on ‘‘soft tissue engi-neering for congenital birth defects in children.’’ Funded
by the European Commission under the Sixth Framework
Program, it commenced on January 1, 2007. The project
unites 15 partner organizations (10 research institutes and
5 companies) from nine European countries.1
Modern tissue engineering approaches will be used to
treat children with congenital structural disorders, such as
spina bifida, urogenital defects, gastroschisis, diaphrag-
matic hernia, and esophageal atresia. Usually, these closure
defects are first diagnosed during routine prenatal ultra-
sound screening. In case of, for example, spina bifida and
diaphragmatic hernia, many pregnant women (parents)
may decide to terminate the pregnancy. In other cases,
the child will be operated on some time after birth and—
depending on the kind and severity of the defect—will
require surgery and/or other treatments throughout
childhood and even into adulthood. Closure defects are
associated with a varying range of morbidity and de-
creased quality of life.2 In the last two decades, in utero fetal
therapy has been performed to reduce long-term morbidity
of the child. At present, a multicenter randomized clinical
trial (RCT) is being performed in the United States to study
maternal–fetal surgery for spina bifida.3 In short, modest
advances have been made in the field of maternal–fetal
surgery for certain structural defects, although these in-
terventions remain experimental.4–6
The EuroSTEC project focuses on both maternal–fetal (or
in utero) as well as neonatal interventions using tissue-
engineered products. Part of the EuroSTEC project design is
an extensive ethical analysis, which will focus on all three
phases of the project—fundamental or in vitro research
(which, for the purposes of this article, will be referred to as
‘‘fundamental research’’), animal experiments, and clinical
trials—and will also look ahead to the application of soft
tissue engineering in clinical practice.
An abstract of this article was previously published in Tissue Engineering Part A, Vol. 14, No. 5, May 2008.
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The ethics of the clinical applicability of tissue engineer-
ing has so far received little attention. Issues that receive a
relatively large amount of attention within the broader
context of tissue engineering are the use of human embry-
onic stem cells and therapeutic cloning.7 The EuroSTEC
project is positioned at the intersection of three fields: (1)
regenerative medicine, (2) research with pregnant women
and fetuses, and (3) research with neonates. All three areas
have their own ethical issues, but because of their overlap in
this project, the combination of these issues may lead us to
be confronted with new ethical challenges. To be able to
respond adequately and timely to possible future moral
issues, a prospective and anticipatory ethical analysis is
paramount.8
In this article, we survey experts’ views on ethical issues
raised by the development of a clinical application of tissue
engineering. From the perspective of an empirically based
ethics, the views of these professionals—all involved in the
EuroSTEC project—are expressly relevant because they
have practical experience of the day-to-day (research on
the) clinical application of tissue engineering. This unique
feature may lead them to identify ethical issues that are
difficult to recognize for those who are not directly involved
in the process. The central objective of this empirical study
was to identify what ethical issues that the experts involved
in research on soft tissue engineering for closure defects
expect to occur during the different phases of the EuroSTEC
project.
Methods
Data collection and analysis
A modified Delphi study was deemed the most suitable
method to survey the ethical issues that the EuroSTEC pro-
fessionals expect to occur during the course of the project.
The Delphi method is a standardized research method.
However, it is common to modify a Delphi study and restrict
the number of rounds to ensure a high response rate
throughout the multiple rounds.9–11 The Delphi method is a
systematic, iterative forecasting method used to collect and
distill knowledge from a group of experts.12 Characteristic of
this qualitative research method is that it takes place over
several rounds, with the answers of one round being used to
formulate questions for the next rounds.
In this case, the first round consisted of a questionnaire
with two sections: (1) six short questions asked for certain
personal information, such as sex, nationality, and role in the
project (respondents were not asked to include their name),
and (2) four open-ended questions. Each of these questions
invited the respondents to list the ethical issues that they
expect to occur during a specific phase of the project (fun-
damental research, animal experimentation, clinical trials,
and clinical practice). For the latter two phases, respondents
were asked to answer for maternal–fetal and neonatal in-
terventions separately.
The research population consisted of all persons involved
in one or more research areas of the EuroSTEC project (which
includes, among others, pediatric urologists, fetal and neo-
natal surgery specialists, obstetricians/gynecologists, animal
research experts, and researchers in the fields of biochemis-
try, biopolymer synthesis, molecular biology, and bioengi-
neering). All professionals involved in the project were
invited to participate in the first round. The questionnaire
was sent to the research population by email several days
before a central research meeting in November 2007. Re-
spondents had the opportunity to return it by email or in
hard copy at the meeting itself.
The results of the first round were initially analyzed by the
primary analyst (A.J.M.O.) and subsequently reviewed by
the second analyst (W.J.M.D.). Respondents’ answers refer-
ring to the same issue were given the same code label.
Subsequently, similar ethical issues were grouped in a cate-
gory. In June 2008, the results were presented to the partic-
ipants. As is customary in a Delphi study, the results of the
first round were used to develop the questionnaire for the
second round.
This second questionnaire consisted of (1) the same six
short questions as in the first questionnaire and (2) a list of
ethical issues distilled from the first round, grouped by re-
search phase. For each ethical issue in the list, respondents
were asked to indicate on a 5-point Likert scale how im-
portant they thought this issue would be during the project
(1 labeled ‘‘not important,’’ 5 labeled ‘‘very important’’).
Again, the entire group of professionals was invited to par-
ticipate, regardless of whether they had responded to the
first-round questionnaire. The second Delphi round was
conducted during a central research meeting in November
2008; the questionnaire was sent to the research population
several days in advance, and respondents had the opportu-
nity to return it by email or in hard copy at the meeting itself.
The results were described and analyzed in the final months
of 2008 by calculating the average score per item (on a scale
of 1 to 5) using SPSS 16.0 software. Product of round 2 was a
list of ethical issues, ranked in order of importance.
Results
Response
The first round saw a response of 29 out of a total of 48
(60.4%). The response rate of the second round was 67.9% (or
38 of 56). There is a discrepancy in total number of ad-
dressees between these rounds, because eight people were
added to the EuroSTEC project between rounds 1 and 2 (for
respondent characteristics, see Table 1).
The first round yielded a total of 27 ethical issues. During
this first round, the questions were divided into four phases:
the fundamental research phase, the animal experimentation
phase, the clinical trial phase, and the clinical practice phase.
However, answers pertaining to the last two phases ap-
peared to be very similar. With exception of certain issues in
the field of research ethics, all pertain to both clinical trials as
well as eventual implementation of tissue engineering in
clinical practice. Therefore, these phases were combined in
the second-round questionnaire (and renamed the ‘‘clinical
[trial] phase’’).
The scores given to the 27 issues in round 2 (on a scale of
1 to 5) ranged from 2.54 to 4.59 (see also Table 5).
Results by research phase
Fundamental research. For the fundamental research
phase, the first round yielded two main categories, named
‘‘source’’ and ‘‘donation,’’ with a total of 10 issues mentioned
(Table 2).
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Source: Six different issues all refer to the source of cells used
in the fundamental research phase. The origin of these
cells appears to be morally problematic or at least morally
relevant to the respondents.
Donation: The second category within this research phase
(entitled ‘‘donation’’) contains four issues that all refer to
some part of the donating process; material received from
a person and used for research or development of a tissue-
engineered product. Often mentioned in this respect were
the protection of the privacy and the need for informed
consent of the tissue donor. Also mentioned, although
much less often, was the possible invasiveness of the
procedure through which tissue is obtained. An example
of this, mentioned by a respondent, is the possible risks
involved in collecting amniotic fluid from a pregnant
woman for the purposes of research.
In terms of ranking by importance, issues directly related
to the tissue donor (privacy and informed consent of the
donor and the invasiveness of the procedure) ranked highly,
taking the 4th, 5th, and 11th place in the overall ranking (of
27 issues in total). The use of excess tissue obtained through
abortion and the use of embryonic and umbilical cord stem
cells were among the lowest ranked (at places 24, 25, and 26,
respectively). The other five issues ranked between places 14
and 20 (see also Table 5).
Animal experimentation. For the animal experimenta-
tion phase the answers given could be brought back to three
issues, grouped under the category of ‘‘use of animals’’
(Table 3). First, as mentioned by almost all respondents, is
the suffering of the animals during experiments, which
ranked highest among the three (and ranked 7th overall).
Second, the instrumental use of animals—as means to an
end—to improve the health of human beings was men-
tioned. Last, the limited adequacy of the animal models was
pointed out, although this was mentioned far less fre-
quently than the first two. The latter two ranked at numbers
18 and 21, respectively.
Clinical (trial) phase. The clinical (trial) phase yielded the
largest amount of issues (14), more than the fundamental
and animal experimentation phase combined. The list of is-
sues could be clustered into five different categories, namely
risk–benefit ratio, parents, material, intervention, and mis-
cellaneous (Table 4).
Risk–benefit ratio: A category of issues mentioned by vir-
tually all respondents was difficulties surrounding the
risk–benefit ratio. In the EuroSTEC project, the ‘‘risk’’ can
be divided into different types of risk. In the case of a
maternal–fetal (or in utero) intervention, there are risks for
both pregnant woman and fetus. As explained by re-
spondents, for the pregnant woman, this means the neg-
ative consequences of a surgical intervention, without
actually experiencing any physical benefits herself. These
risks include miscarriage and preterm delivery after the
procedure, and the risk of bodily injury associated with
any surgical intervention. The risks for the fetus include,
again, spontaneous abortion or preterm delivery, with
associated consequences of severe morbidity or death of
the fetus, and the risk of bodily injury.
In addition to risks associated with the surgical interven-
tion, respondents indicated that the materials used carry
certain risks with them. The collagen used, derived from
bovine tendon, may lead to infection with certain viruses. In
addition, there appear to be some questions as to whether
Table 1. Respondent Characteristics
Round 1
(n¼ 29)
Round 2
(n¼ 38)
Sex (% male) 20 (69.0) 28 (73.7)
Nationality
Austrian — 4
Dutch 11 13
French 1 2
German 3 3
Swedish 3 4
Swiss 7 6
Other 4 4
Educational background (%)
Sciences 16 (55.2) 24 (63.2)
Medicine 8 (27.6) 13 (34.2)
Other 5 (17.2) 1 (2.6)
Involved ina (%)
Fundamental research 22 (75.9) 27 (71.1)
Animal experimentation 6 (20.7) 14 (36.8)
Clinical (trial) phase 4 (13.8) 5 (13.2)
Place of work (%)
University/hospital 25 (86.2) 33 (86.8)
Industry 4 (13.8) 5 (13.2)
aSome respondents are involved in multiple research phases.
Table 2. Results—Fundamental Research Phase
Category Issue Ranka
Source  The use of fetal cells 14
 The use of cells from neonates 15
 The use of fetal stem cells 19
 The use of excess tissue obtained
through abortion
24
 The use of embryonic stem cells 25
 The use of umbilical cord stem cells 26
Donation  Privacy of the donor of tissue 4
 Informed consent of the donor of tissue 5
 The possible invasiveness
of the procedure through
which tissue is obtained
11
 Unclarity about the ownership
of donated tissue
20
aOut of a total of 27 ethical issues.
Table 3. Results—Animal Experimentation Phase
Category Issue Ranka
Use of animals  The suffering of animals 7
 The use of animals as means
to an end
18
 The limited adequacy/
extrapolation of the
animal models
21
aOut of a total of 27 ethical issues.
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the use of certain cells could give rise to the development of
tumors later in life.
However, the maternal–fetal intervention has numerous
possible benefits, both for the future child and the pregnant
woman. As pointed out by several respondents, the future
child may need fewer or no more surgical procedures later in
life, or may even survive where it would have died with
conventional treatment. Benefits for the pregnant woman
include, for example, an improved psychological well-being
due to having a healthier child. As pointed out by the re-
spondents, the ethical question is how we balance the risks
against the benefits, especially because so little is known
about some of the risks.
Parents: The category we called ‘‘parents’’ comprises three
different issues all somewhat related to the parents’ in-
volvement in decision making regarding participation of
their fetus or child in clinical research or consenting to
treatment of this child. Respondents indicated that parents
may experience discomfort or feel pressured by the re-
searcher and/or physician (ranked 9th). Also mentioned
was the impossibility of fully informing the parents of the
risks involved in procedures using tissue-engineered
products (number 13 on the ranking list), because the
technology is complex and difficult to understand, espe-
cially for lay people, and particularly at a time of intense
pressure. Mentioned only once was the matter of re-
specting parents’ religious beliefs when dealing with their
views about the use of certain materials (from animal
sources) in their (unborn) child (ranked 23rd).
Material: Two issues were grouped under ‘‘material,’’ both
initially mentioned by only a few respondents. First, the use
of animal material inside the human body or, as one re-
spondent put it, the ‘‘mixing of humans and animals’’ was
identified as an ethical issue. Second, one respondent
mentioned possible objections against the use of animal
material (or rather, material from certain specific types of
animals) for religious reasons. Incidentally, these two issues
were ranked low compared with the other issues, placing at
positions 22 and 27 of the ranking list, respectively.
Intervention: A fourth category of ethical issues refers to
difficulties surrounding the determination of the right time
of intervention. Although it may seem like a medical–
technical question, it does have a moral layer, as discus-
sions about the right timing of an intervention are related to
the moral status of the fetus and the idea that it is gradual
and dependent on viability. In the discussion we will return
to the respondents’ phrasing of the ethical issues.
An issue that came up repeatedly—and was deemed the
most important issue during the second round—was the
dilemma of choosing between termination of pregnancy and
surgical intervention with poor long-term quality-of-life
prospects for the child.
Several professionals involved in clinical research and/or
clinical practice mentioned the issue of determining the right
timing of a maternal–fetal intervention. This in effect is re-
lated to weighing risks and benefits of the two options—
respondents named the example of spina bifida, in which
early intervention (i.e., covering of the defect) diminishes
secondary damage to the spinal cord due to prolonged ex-
posure of the neuronal tissue to amniotic fluid, but which in
turn might lead to delivery before the fetus is viable. If one
were to intervene later in the pregnancy, even when the fetus
has a chance of survival if born prematurely, secondary
damage to the spinal cord would have already occurred.
Another issue mentioned is the difficulty of determining
how severe a defect should be for a surgical intervention to
Table 4. Results—Clinical Phase
Category Ethical issues Ranka
Risk–benefit ratio  Weighing risks for the mother against possible benefits for the unborn child 2
 Weighing risks for the fetus/neonate against possible benefits for the fetus/neonate 3
 Weighing the possible risks and benefits of a maternal–fetal intervention against those
of a neonatal intervention
6
Parents  The possible pressure or discomfort experienced by parents during the decision-making
process concerning the participation of their child in a clinical trial
9
 The impossibility of fully informing parents of the risks involved in trials/clinical
applications of tissue engineering
13
 Respecting parents’ religious beliefs 23
Material  The ‘‘mixing’’ of animals and humans through the introduction of animal material
into the human body
22
 Religious objections to the use of animal material inside the human body 27
Intervention  The dilemma of choosing between terminating the pregnancy, on the one hand,
and surgical intervention with poor long-term quality-of-life prospects for the child,
on the other hand
1
 Weighing the possible risks and benefits of early intervention during pregnancy against
those of intervention later in pregnancy
8
 Difficulty of determining how severe a defect should be for a surgical intervention
to be required/unavoidable
10
Miscellaneous  Determining the right moment to cease clinical research and implement the intervention
in clinical practice
12
 Rights of the fetus 16
 Distributive justice 17
aOut of a total of 27 issues.
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be required. In some cases, the defect is nonlethal but comes
with considerable morbidity. Respondents questioned whe-
ther we should then take the risk of intervening in utero, with
a possibly better long-term quality-of-life prospect, but also
with the risks of infection and premature delivery associated
with a maternal–fetal intervention. In other words, if a neo-
natal intervention is an option, should we still want to per-
form a maternal–fetal intervention?
All three issues ranked relatively highly, at numbers 1, 8,
and 10, respectively.
Miscellaneous: Several uncategorized issues were grouped
under ‘‘miscellaneous.’’ An issue mentioned once was
distributive justice or, as the respondent put it, ‘‘will this
only be available to the richest, or is it for everyone?’’
(ranked 17th). Mentioned more frequently were the so-
called ‘‘rights of the fetus’’ (ranking at number 16).
An issue that pertains specifically to clinical trials is de-
ciding on the right moment to cease clinical research and
implement the intervention in clinical practice. As several
respondents indicated, this should not be done too early,
because enough evidence of the risks and benefits associated
with the treatment should be available. On the other hand, it
would be a shame to wait too long, because it would delay
the potential good that can be done.
Discussion
Our Delphi study yielded a total of 27 ethical issues. Some
issues were rather nonspecific, such as ‘‘informed consent of
tissue donor’’ for the fundamental research phase or ‘‘the
suffering of animals’’ for the animal experimentation phase.
Others—like many of the 14 mentioned for the clinical
phase—more specifically related to the EuroSTEC project,
because they pertained to either tissue engineering research,
or research with fetuses or neonates (or a combination of
both). As mentioned previously, the project is positioned at
the intersection of different fields with their own ethical is-
sues. It is interesting to note that the issues deemed most
important are not specific to tissue engineering research, but
to research with pregnant women and fetuses and neonates.
Some of the issues mentioned were more in the realm of
morally relevant facts and problems than true ethical issues.
An example is ‘‘the possible invasiveness of the procedure
Table 5. Round 2 Results—Overall Ranking
Rank Ethical issue Average scorea
1 The dilemma of choosing between terminating the pregnancy, on the one hand, and
surgical intervention with poor long-term quality-of-life prospects for the child, on
the other hand
4.59
2 Weighing risks for the mother against possible benefits for the unborn child 4.49
3 Weighing risks for the fetus/neonate against possible benefits for the fetus/neonate 4.47
4 Privacy of the donor of tissue 4.38
5 Informed consent of the donor of tissue 4.34
6 Weighing the possible risks and benefits of a maternal–fetal intervention against
those of a neonatal intervention
4.22
7 The suffering of animals 4.21
8 Weighing the possible risks and benefits of early intervention during pregnancy
against those of intervention later in pregnancy
4.21
9 The possible pressure or discomfort experienced by parents during the decision-
making process concerning the participation of their child in a clinical trial
4.20
10 Difficulty of determining how severe a defect should be for a surgical intervention to
be required/unavoidable
4.19
11 The possible invasiveness of the procedure through which tissue is obtained 4.11
12 Determining the right moment to cease clinical research and implement the
intervention in clinical practice
4.11
13 The impossibility of fully informing parents of the risks involved in trials/clinical
applications of tissue engineering
4.09
14 The use of fetal cells 4.08
15 The use of cells from neonates 4.06
16 The rights of the fetus 4.00
17 The problem of distributive justice; to whom should treatment be offered? 3.97
18 The use of animals as means to an end 3.92
19 The use of fetal stem cells 3.89
20 Unclarity about the ownership of donated tissue 3.63
21 The limited adequacy/extrapolation of the animal models 3.62
22 The ‘‘mixing’’ of animals and humans through the introduction of animal material
into the human body
3.49
23 Respecting parents’ religious beliefs 3.47
24 The use of excess tissue obtained through abortion 3.39
25 The use of embryonic stem cells 3.34
26 The use of umbilical cord stem cells 2.97
27 Religious objections to the use of animal material inside the human body 2.54
aOn a scale from 1 to 5, with 1 labeled ‘‘not important’’ and 5 labeled ‘‘very important.’’
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through which tissue is obtained’’: although the implications
of risks associated with a procedure do inform the moral
judgments about the acceptability of the procedure, the in-
vasiveness itself is not an ethical issue in the strict sense of
the word. Our participants were not ethicists and may have
had some trouble identifying ethical issues in their practice
and phrasing them in the questionnaire. In addition, the fact
that we used a questionnaire as method of data collection
most likely had some influence: written questionnaire an-
swers are usually somewhat concise (more concise than, e.g.,
during a face-to-face interview). This may have caused par-
ticipants to phrase their answers as morally relevant facts
and problems, whereas if they were to elaborate further, the
underlying ethical issue would become more explicit.
Therefore, we did include these morally relevant items in our
analysis.
In a previous literature study focusing on ethical aspects
of tissue engineering,7 an overwhelming majority of papers
was found to focus solely on the use of human embryonic
stem cells or therapeutic cloning, while other ethical issues
received little attention. It was argued that the most pressing
matter at this time were ethical questions related to clinical
trials, because of the current stage of development of the
field of tissue engineering. Trommelmans et al.13,14 too ar-
gued that these issues have so far received relatively little
attention.
A recent publication by Trommelmans et al. reported on a
survey conducted among participants of a consortium of
universities and enterprises focusing on tissue engineering of
skin, cartilage, bone, and viscera.15 Participants were asked
for their opinion on the need for development of ethical
guidance and were presented with statements concerning
clinical trials. Our study took a more bottom-up approach:
we started by asking the participants to name ethical issues,
instead of presenting them with a fixed list. Based on their
study, Trommelmans et al. argued that clinical trial issues are
in need of more profound reflection, a conclusion we endorse
based on our own research.
As evidenced by our priority list—issues more or less re-
lated to clinical trials were in the top half of this list—tissue
engineering professionals too consider these issues to be of
great importance. Both previously cited articles and our
participants note that the complexity of tissue-engineered
products poses challenges to meeting the requirements of
informed consent (for donors as well as recipients of tissue/
tissue-engineered products) and making an accurate risk–
benefit analysis. We believe that the ethical challenges in
clinical trials are in most immediate need of attention, both
from tissue engineers and ethicists.
It might be objected that knowledge gained from the two
Delphi rounds was—by nature of those rounds—more broad
than deep. However, this was our explicit objective, to give
an initial survey of the full range of ethical issues expected by
people with experience in tissue engineering research. The
mere wording of some of the respondents’ answers request
further explanation in face-to-face conversations. An exam-
ple of this would be the issue ‘‘the rights of the fetus.’’ Al-
though it may seem a rather straightforward concept, by
using the term ‘‘right’’ in combination with ‘‘fetus,’’ a certain
interpretation of the entity ‘‘fetus’’ as a subject with rights is
implied. Future research—in the form of focus groups—will
aim to deepen this knowledge and explore the issues further.
Our research population consisted of a diverse group of
tissue engineering professionals: participants were involved
in fundamental research, animal experiments, and/or clinical
research, and many different countries, nationalities, occu-
pations, and institutions were represented. In future empir-
ical research, we wish to extend the target population to
include other groups, such as tissue engineering experts
outside of the EuroSTEC project. Additionally, the views of
ethicists and of prospective patients and/or their parents are
lacking in this study. It is our explicit intention to include
them in future research.
Ethics of tissue engineering and regenerative medicine
remain a relatively small field. This study was one of the first
to feature a survey of tissue engineering professionals’ views
on ethical aspects of a clinical application of tissue engi-
neering. Although the participants of this Delphi study were
recruited from one specific project, we feel the relevance of
our results is not limited to this project. Numerous parallels
can be drawn between the project at hand and any other
(pre)clinical study in the field of tissue engineering. The full
list of ethical issues is unique to the research of EuroSTEC,
but, for example, issues pertaining to animal experiments
with tissue-engineered products will be of interest to those
conducting these types of experiments. Those involved in
clinical trials in this field will find the ethical issues that refer
to this phase relevant to their own research. Therefore, we
feel our study will be of relevance to research on applications
of tissue engineering in general.
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